Interim report Q2, 2025: Strong performance across Consumables

Second quarter

• Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.
• Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC.
• Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics.
• Sales per product group, in local currencies was +5% in Consumables, -8% in Technologies and 0% in Genetics.
• Gross margin decreased to 58.0% (59.9) also negatively impacted by currency.
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 243 (327) million, resulting in an EBITDA margin of 27.8% (34.7), significantly impacted by negative currency effect.
• Operating cash flow amounted to SEK 151 million (236).
• Net income was SEK 100 (143) million, resulting in earnings per share of SEK 0.74 (1.06).
• Vitrolife AB (publ) acquired a leading stake in AutoIVF.

First half year

• Sales of SEK 1,714 (1,782) million, a flat growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -4%. Organic growth in local currencies excluding discontinued business was 3%.
• Sales per region, in local currencies was +2% in EMEA, +10% excluding discontinued business, +7% in Americas and -8% in APAC.
• Sales per product group, in local currencies excluding discontinued business was +7% in Consumables, -6% in Technologies and +4% in Genetics.
• Sales per product group, in local currencies was +4% in Consumables, -7% in Technologies and +1% in Genetics.
• Gross margin decreased to 57.7% (58.6) also negatively impacted by currency.
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 500 (600) million, resulting in an EBITDA margin of 29.2% (33.6), significantly impacted by negative currency effect.
• Operating cash flow amounted to SEK 220 million (434).
• Net income was SEK 199 (258) million, resulting in earnings per share of SEK 1.48 (1.91).

Gothenburg, July 17, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2025 08:00 CET.